Thursday, December 17, 2020 5:19:13 PM
Presentation - Durable Responses in Patients with Synovial Sarcoma in the Phase 1 Trial of ADP-A2M4 (MAGE-A4) https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/CTOS_BVT_29Oct2020_FINAL_FINAL.pdf
The Synovial Sarcoma Subset Analysis of the Multi-Histology Phase I Trial of ADP-A2M4 (MAGE-A4) https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jill+Rogers+-+Van+Tine_CTOS_ADP-A2M4+SS_11Nov2019+%28clean%29.pdf
SITC:
Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10 S+PEAR T-Cells in Patients with MAGE-A10 Advanced Non-Small Cell Lung Cancer https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+NSCLC+eposter_G+Blumenschein+SITC+%28CLH07%29+FINAL+UPLOAD+copy.pdf
Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10+ SPEAR T-Cells in Patients with MAGE-A10 Head and Neck, Melanoma, or Urothelial Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+Triple+Tumor+eposter_D+Hong+SITC+%28CM07%29+FINAL+UPLOAD+copy.pdf
Inhibition of AKT Signaling During Expansion of TCR-Engineered T-Cells from Patient Leukocyte Material Generates SPEAR T-Cells with Enhanced Functional Potential In Vitro https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+DP005-20++SITC+2020+AKTi+eposter+CM07+copy.pdf
Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8a Co-Receptor https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+SURPASS+eposter_SITC+2020_D+Hong+et+al+%28cm08%29+FINAL_UPLOAD+copy.pdf
Case Reports: Correlates of Response Following Adoptive Transfer of ADP-A2M4, Affinity-Enhanced T-Cells Targeting MAGE-A4 in Synovial Sarcoma https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+Case+Reports+Poster_FINAL.pdf
SPEARHEAD-1 Trial Design: A Phase 2, Single-Arm, Open-Label Clinical Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+SPEARHEAD-1+Trial+Poster_FINAL.pdf
SURPASS Trial Design: A Phase 1 Dose Escalation Trial to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Patients with MAGE-A4+ Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+Case+Reports+Poster_FINAL.pdf
Recent ADAP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:15:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 11:23:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:05:55 AM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 11:00:19 AM
- Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor • Business Wire • 08/02/2024 12:20:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:39:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:14:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:34:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:31:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:46:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM